ProCE Banner Activity

CE / CME

Assessing Measurable Residual Disease in Chronic Lymphocytic Leukemia

Text Module

In this focused text module, expert faculty discuss the latest information on measurable residual disease testing and clinical use in the care of patients with CLL.

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: August 30, 2022

Expiration: August 29, 2023

No longer available for credit.

Share

Faculty

Nichole Fisher

Nichole Fisher, RN, BSN

Supervisor, Clinical Research
Willamette Valley Cancer Institute & Research Center
Eugene, Oregon 

Anthony Perissinotti

Anthony Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
Clinical Team Leader
, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan

Jennifer Woyach

Jennifer Woyach, MD

Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Eli Lilly

Janssen Biotech

Pharmacyclics an AbbVie Company

TG Therapeutics

Partners

CLL Society

ProCE Banner

Target Audience

This educational program is intended for physicians, nurses, pharmacists, healthcare professionals, patients, and caregivers involved in the management of CLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Foster collaborative discussions between patients/caregivers and HCPs on guidelines and recent clinical evidence to guide personalized treatment planning for treatment-naive and relapsed/refractory CLL

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Nichole Fisher, RN, BSN

Supervisor, Clinical Research
Willamette Valley Cancer Institute & Research Center
Eugene, Oregon 

Nichole Fisher, RN, BSN: consultant: AbbVie, TG Therapeutics.

Anthony Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
Clinical Team Leader
, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan

Anthony Perissinotti, PharmD, BCOP: consultant: AbbVie, Janssen.

Jennifer Woyach, MD

Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Jennifer Woyach, MD: consultant: AbbVie, ArQule, AstraZeneca, BeiGene, Janssen, MorphoSys, Pharmacyclics; researcher: AbbVie, Karyopharm, Loxo, MorphoSys, Verastem.

Staff Disclosure

Staff

Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kristi Kay Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, MorphoSys, Pfizer, Regeneron, Sanofi.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Jill A. Sakai,

Contributing Editor

Jill Sakai, PhD, has no relevant financial relationships to disclose.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant financial relationships to disclose.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-217-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 30, 2022, through August 29, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the competence of learners in educating and managing patients with chronic lymphocytic leukemia.